Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: An active drug combination with major nonhematologic toxicity

D. C. Ihde, M. H. Cohen, P. A. Bunn, A. M. Bernath, L. E. Broder, J. D. Minna

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)155-157
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number1
StatePublished - Sep 15 1978

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this